Clinical Trials Browser

Carcinoma, Renal Cell × Everolimus × Endocrine × Clear all

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Phase 1 Recruiting

27 enrolled

EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

96 enrolled

DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT01115803 2019-02-05

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Phase 1 Terminated

29 enrolled 19 charts

EndocrineGenitourinaryNETThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors